Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Riethdorf, Sabine ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; DISSEMINATED CANCER; HORMONAL THERAPY; HUMAN; METASTASIS; PRIMARY TUMOR; SOLID TUMOR; TUMOR CELL; BLOOD; BONE MARROW CELL; BREAST TUMOR; FEMALE; MEDICAL RESEARCH; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PATHOLOGY; TUMOR EMBOLISM;

BIOMEDICAL RESEARCH; BONE MARROW CELLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING;

EID: 77951930433     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2429     Document Type: Article

References (89)

1. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340. 10.1038/nrc2375, 18404148.
2. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastasis. Nat Clin Pract Oncol 2009, 6:339-351.
3. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456. 10.1038/nrc1370, 15170447.
4. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993, 85:1419-1424. 10.1093/jnci/85.17.1419, 7688814.
5. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11:3678-3685. 10.1158/1078-0432.CCR-04-2469, 15897564.
6. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006, 18:48-56. 10.1097/01.cco.0000198973.51615.fa, 16357564.
7. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008, 14:5013-5021. 10.1158/1078-0432.CCR-07-5125, 18698019.
8. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006, 13:1033-1067. 10.1677/ERC-06-0001, 17158753.
9. Alix-Panabieres C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 2007, 19:558-563. 10.1097/CCO.0b013e3282f0ad79, 17906452.
10. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123:1991-2006. 10.1002/ijc.23825, 18712708.
11. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998, 185:427-434. 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7, 9828843.
12. Borgen E, Naume B, Nesland JM, Nowels KW, Pavlak N, Ravkin I, Goldbard S. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 2001, 46:215-221. 10.1002/cyto.1130, 11514954.
13. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006, 107:885-892. 10.1002/cncr.22076, 16874814.
14. Borgen E, Pantel K, Schlimok G, Muller P, Otte M, Renolen A, Ehnle S, Coith C, Nesland JM, Naume B. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006, 70:400-409.
15. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, Fabbro M, Pantel K. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007, 53:537-539. 10.1373/clinchem.2006.079509, 17327507.
16. Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. Full length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009, 11:R39. 2716508, 19549321, 10.1186/bcr2326.
17. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
18. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904. 10.1158/1078-0432.CCR-04-0378, 15501967.
19. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430. 10.1200/JCO.2005.08.140, 15735118.
20. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
21. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053-7058. 10.1158/1078-0432.CCR-07-1506, 18056182.
22. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
23. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:2023-2029. 10.1158/1078-0432.CCR-06-2701, 17404082.
24. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, Garcia-Saenz JA, Vidaurreta M, Martin M, Arroyo M, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008, 19:935-938. 10.1093/annonc/mdm583, 18212090.
25. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239. 10.1038/nature06385, 18097410.
26. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Hoffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005, 43:617-627. 10.1515/CCLM.2005.107, 16006258.
27. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH. A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004, 101:10501-10504. 489966, 15249663, 10.1073/pnas.0404036101.
28. Curry DN, Krivacic RT, Hsieh HB, Ladanyi A, Bergsrud DE, Ho MY, Chen LB, Kuhn P, Bruce RH. High-speed detection of occult tumor cells in peripheral blood. Conf Proc IEEE Eng Med Biol Soc 2004, 2:1267-1270.
29. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, Nieva J. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21:1893-1899. 10.1016/j.bios.2005.12.024, 16464570.
30. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009, 106:3970-3975. 2645911, 19234122, 10.1073/pnas.0813188106.
31. Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, Coombes RC. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997, 33:854-861. 10.1016/S0959-8049(97)00014-2, 9291805.
32. Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000, 18:1432-1439.
33. Berois N, Varangot M, Aizen B, Estrugo R, Zarantonelli L, Fernandez P, Krygier G, Simonet F, Barrios E, Muse I, Osinaga E. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer 2000, 36:717-723. 10.1016/S0959-8049(99)00338-X, 10762743.
34. Zhong XY, Kaul S, Lin YS, Eichler A, Bastert G. Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19. J Cancer Res Clin Oncol 2000, 126:212-218. 10.1007/s004320050035, 10782894.
35. Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, Scanni A, Deliliers GL. Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev 2002, 26:60-63. 10.1016/S0361-090X(02)00009-0, 12088204.
36. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF. Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR. Clin Chem 2004, 50:785-786. 10.1373/clinchem.2003.025510, 15044349.
37. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 14:2593-2600. 10.1158/1078-0432.CCR-07-4758, 18451221.
38. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009, 27:2177-2184. 10.1200/JCO.2008.18.0497, 19332733.
39. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59. 2750121, 19664291, 10.1186/bcr2349.
40. Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 2004, 5:79-88. 10.1016/S1470-2045(04)01381-6, 14761811.
41. Balducci E, Azzarello G, Valori L, Toffolatti L, Bolgan L, Valenti MT, Bari M, Pappagallo GL, Ausoni S, Vinante O. A new nested primer pair improves the specificity of CK-19 mRNA detection by RT-PCR in occult breast cancer cells. Int J Biol Markers 2005, 20:28-33.
42. Ballestrero A, Garuti A, Bertolotto M, Rocco I, Boy D, Nencioni A, Ottonello L, Patrone F. Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer 2005, 92:1948-1952. 2361769, 15841077, 10.1038/sj.bjc.6602563.
43. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683-689. 10.1016/S0140-6736(02)09838-0, 12241875.
44. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003, 100:7737-7742. 164657, 12808139, 10.1073/pnas.1331931100.
45. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991, 51:4712-4715.
46. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmüller G. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002, 20:387-392. 10.1038/nbt0402-387, 11923846.
47. Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 2003, 107:903-909. 10.1002/ijc.11488, 14601049.
48. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 2003, 9:2598-2604.
49. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, Pantel K. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004, 10:3422-3428. 10.1158/1078-0432.CCR-03-0610, 15161697.
50. Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005, 114:291-298. 10.1002/ijc.20698, 15543615.
51. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006, 103:17361-17365. 1838539, 17079488, 10.1073/pnas.0608113103.
52. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737.
53. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904. 10.1038/nm1469, 16892035.
54. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001, 61:1890-1895.
55. Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Freneaux P, Dieras V, Thiery JP, Sastre-Garau X. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. Br J Cancer 2007, 96:654-659. 2360046, 17262082, 10.1038/sj.bjc.6603584.
56. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, Neubauer H, Wallwiener D, Huober J, Fehm TN. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006, 98:179-184. 10.1007/s10549-005-9147-y, 16552629.
57. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398. 438987, 15194824, 10.1073/pnas.0402993101.
58. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006, 12:1715-1720. 10.1158/1078-0432.CCR-05-2087, 16551854.
59. Riethdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K, Muller V. Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2-positive tumors - a translational project within the study 'GeparQuattro' [abstract 5025]. Breast Cancer Res Treat 2007, 106(Suppl 1):S214.
60. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65:4993-4997. 10.1158/0008-5472.CAN-04-4330, 15958538.
61. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002, 161:1881-1891. 1850763, 12414534.
62. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279. 10.1016/j.cell.2004.07.011, 15294153.
63. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67:1979-1987. 10.1158/0008-5472.CAN-06-1479, 17332325.
64. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007, 67:9066-9076. 2570961, 17909010, 10.1158/0008-5472.CAN-07-0575.
65. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007, 13:5001-5009. 2680916, 17785550, 10.1158/1078-0432.CCR-07-0024.
66. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621. 10.1158/1078-0432.CCR-06-0169, 17020963.
67. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46. 2750105, 19589136, 10.1186/bcr2333.
68. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000, 18:80-86.
69. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004, 10:5342-5348. 10.1158/1078-0432.CCR-04-0245, 15328170.
70. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005, 103:884-891. 10.1002/cncr.20834, 15666325.
71. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. 10.1056/NEJMoa050434, 16120859.
72. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
73. Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004, 10:3091-3097. 10.1158/1078-0432.CCR-03-0373, 15131048.
74. Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005, 114:94-100. 10.1002/ijc.20655, 15523696.
75. Janni W, Wiedswang G, Fehm T, Jueckstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland JM, Genss E, Friese K, Naume B. Persistence of disseminated tumor cells (DTC) in bone marrow (BM) during follow-up predicts increased risk for relapse up-date of the pooled European data [abstract 18]. Breast Cancer Res Treat 2006, 100(Suppl 1):S11.
76. Naume B, Fehm T, Wiedswang G, Jückstock J, Borgen E, Rack B, Synnestvedt M, Braun S, Sommer H, Solomayer E, Pantel K, Friese K, Janni W. Persistence of isolated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Cancer Res 2009, 69 (2 Suppl).
77. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, De Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306-3311. 10.1158/1078-0432.CCR-07-4749, 18519757.
78. Bidard FC, Kirova YM, Vincent-Salomon A, Alran S, de Rycke Y, Sigal-Zafrani B, Sastre-Garau X, Mignot L, Fourquet A, Pierga JY. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 2009, 20:1836-1841. 10.1093/annonc/mdp200, 19556319.
79. Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM, Naume B. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006, 118:2013-2019. 10.1002/ijc.21576, 16287086.
80. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, Thiery JP, Sastre-Garau X, Pierga JY. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008, 19:496-500. 10.1093/annonc/mdm507, 18187488.
81. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004, 10:1392-1400. 10.1158/1078-0432.CCR-0102-03, 14977842.
82. Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, Palmieri C, Sinnett HD, Kulinskaya E, Pitfield T, McCormack RT, Pantel K, Coombes RC. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 2009, 100:160-166. 10.1038/sj.bjc.6604773, 19034279.
83. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409. 10.1158/1078-0432.CCR-05-1769, 17085652.
84. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009, 27:3303-3311. 10.1200/JCO.2008.19.4423, 19451443.
85. SWOG-S0500 Trial. , http://www.cancer.gov/clinicaltrials/SWOG-S0500
86. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008, 14:7004-7010. 10.1158/1078-0432.CCR-08-0030, 18980996.
87. Muller V, Riethdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K. Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy - a translational project of the German breast Group study GeparQuattro [abstract]. J Clin Oncol 2007, 25(Suppl):21085.
88. Rack BK, Schindlbeck C, Schneeweiss A, Hilfrich J, Lorenz R, Beckmann MW, Pantel K, Lichtenegger W, Sommer HL, Janni WJ. Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the German SUCCESS-Trial [abstract]. J Clin Oncol 2008, 26(Suppl):503.
89. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, , Marth C. ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681, ABCSG-12 Trial Investigators.